在LPS诱导的H9C2损伤中,由miR-497-5p/BTRC/IκBα轴介导的NF-κB通路激活引起的甲福尔明的保护功能
Fan Xiao-Guang1, Li Shu-Yuan2, Cui Wen-Juan1
1Intensive Care Unit, Shengli Oilfield Central Hospital, Dongying, Shandong, China.
The Journal of pharmacology and experimental therapeutics
|October 6, 2025
概括
甲胺通过减少炎症来保护心脏细胞免受败血症引起的损伤. 它通过增加microRNAmiR-497-5p起作用,抑制BTRC蛋白并抑制NF-κB炎症途径.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 败血症引起的心肌功能障碍是死亡的主要原因.
- 甲福明是一种抗糖尿病药物,显示出潜在的心脏保护作用.
- 了解梅特福林在败血症中的机制对于治疗开发至关重要.
研究的目的:
- 调查甲福明在心肌细胞中对脂聚糖 (LPS) 诱导的损伤的保护作用.
- 阐明潜在的分子机制,重点关注微RNA和炎症途径.
主要方法:
- 使用了H9C2和AC16心肌细胞细胞系.
- 使用LPS诱导的损伤和炎症.
- 评估了细胞活力,细胞亡和炎症性细胞因子水平.
- 通过敲击和过度表达实验,研究了microRNAmiR-497-5p和BTRC (含有E3无素蛋白联酶的β-转化素重复) 的作用.
- 分析了NF-κB通路的激活.
主要成果:
- 暴露于LPS降低了细胞活力,增加了细胞灭亡,并上调了促炎细胞因子 (TNFα,IL-6,IL-1β).
- 甲胺治疗缓解了LPS诱导的细胞毒性和炎症.
- 甲胺上调 miR-497-5p,抑制 BTRC 表达,抑制 IκBα 降解和 NF-κB 激活.
- miR-497-5p敲击或BTRC过度表达逆转了甲胺的保护作用.
结论:
- 甲胺保护心肌细胞免受LPS诱导的损伤和炎症.
- 保护机制涉及miR-497-5p/BTRC轴,导致NF-κB通路的抑制.
- 这项研究强调了miR-497-5p和BTRC作为形素在败血症期间心脏保护的关键参与者.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
583
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
583
02:26NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K